Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: R. C. M. is a patent holder for an investigational dengue virus vaccine (US Patent 9,005,633 B2) and receives research funding for clinical trials paid to his institution from AiCuris, Biotest, and GeoVax, including funding for a clinical trial of an investigational SARS-CoV-2 vaccine. R. C. M. has served on a scientific advisory board for Shionogi, unrelated to the current manuscript. R. C. M. is a member of the American Board of Internal Medicine Examination Approval Committee for Critical Care Medicine. None declared (B. G.).